Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

Ashfaq Marghoob provides skin cancer care to the residents of Long Island at MSK’s dedicated skin ... It is particularly effective for high-risk squamous cell carcinomas, such as large, deep tumors; ...

hepatocellular carcinoma (HCC), glioblastoma multiforme (GBM), acute myelocytic leukemia, relapsed and refractory acute myeloid leukemia, primary mediastinal large B-cell lymphoma, triple negative ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...